Evaxion A/S (EVAX) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evaxion A/S is the larger company by market cap ($27.7 million vs $27.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | MCRB |
|---|---|---|
| Share price | $3.07 | $2.71 |
| Market cap | $27.70M | $27.22M |
| 1-day change | +0.66% | +3.04% |
| YTD return | -36.06% | — |
| 1-year return | -51.51% | — |
| 5-year return | -99.23% | — |
| EPS (TTM) | $-1.01 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $29.98 |
| 52-week low | $2.77 | $2.42 |
| Distance from 52-week high | -74.73% | -90.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +266.45% | +527.31% |
| Average volume | 200.14K | 73.43K |
| Shares outstanding | 9.02M | 10.04M |
| Employees | 46 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
EVAX vs MCRB FAQ
Which is bigger, Evaxion A/S or Seres Therapeutics?
Evaxion A/S (EVAX) is larger, with a market capitalization of $27.70M compared with $27.22M for Seres Therapeutics (MCRB).
Are Evaxion A/S and Seres Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Evaxion A/S and Biotechnology: Pharmaceutical Preparations for Seres Therapeutics.